FitLife Brands, Inc. — Q1 2015 Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands develops and distributes nutritional supplements under the NDS, PMD, SirenLabs, and CoreActive brands, primarily through franchised GNC stores in the United States and internationally. The filing covers the three months ended March 31, 2015. The interim financial statements are unaudited and include normal recurring adjustments; results are not necessarily indicative of full-year performance.
The company reported 8,082,971 common shares outstanding as of May 12, 2015 and trades on the OTCBB under the symbol FTLF.
Financial Performance and Position
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $3.842 million | $6.333 million | Down 39.3% |
| Gross profit | $1.576 million | $2.357 million | Down 33.1% |
| Gross margin | 41.0% | 37.2% | Up approximately 3.8 points |
| Operating income | $(15,614) | $926,636 | Declined to an operating loss |
| Net income (loss) | $(42,263) | $893,346 | Declined to a net loss |
| Basic and diluted EPS | $(0.01) | $0.11 and $0.10 | Declined |
| Cash flow from operations | $407,391 | $72,242 | Increased |
Operating expenses increased 11.3% to $1.591 million. General and administrative expense rose to $932,246, primarily due to non-cash stock and option compensation. Selling and marketing expense increased to $603,804, principally due to higher product rebate volume. Interest expense was $20,648, compared with $25,018 in the prior-year quarter. The company recorded $6,000 of income tax expense in Q1 2015.
As of March 31, 2015, cash was $4.378 million, total current assets were $9.162 million, and total assets were $10.153 million. Accounts receivable increased to $2.385 million from $1.686 million at December 31, 2014, while inventory declined to $1.654 million from $2.285 million. Working capital was approximately $7.137 million, based on the company’s MD&A.
Total debt was $2.259 million, consisting of a $437,089 revolving line of credit and a $1.822 million term loan. Current debt was $948,697 and long-term debt was $1.310 million. The revolving line of credit matures May 15, 2015 and bears interest at 3.0% plus one-month LIBOR. The term loan bears fixed interest at 3.6% and matures August 15, 2018.
Stockholders’ equity was $6.818 million, compared with $6.714 million at December 31, 2014. The accumulated deficit was $19.691 million. The company held a deferred tax asset of $689,000, supported by a valuation allowance against most net operating loss benefits.
Material Changes Versus the Prior Comparable Period
- Revenue decreased $2.491 million, or 39.3%, primarily because of GNC-related pricing discounts, approximately $1.5 million of non-recurring customer inventory build-up in Q1 2014, and a reported $1.3 million order backlog at the beginning of Q2 2015 caused by short-term supply disruptions.
- Gross margin improved to approximately 41.0% from 37.2%, reflecting lower direct costs associated with the GNC centralized distribution transition, partially offset by lower sales volume.
- Operating income declined from $926,636 to a $15,614 operating loss. Net income declined from $893,346 to a $42,263 net loss.
- General and administrative expense increased because of non-cash stock compensation and option expense. Excluding non-cash issuance costs, management stated that general and administrative expense decreased to $529,835 from $718,893.
- Cash provided by operations increased to $407,391 from $72,242, supported by inventory reductions and other working-capital changes, despite the net loss.
- The company used $255,981 to repurchase 120,354 shares during the quarter under its repurchase program. As of May 8, 2015, the average repurchase price was $2.13 per share.
- The company issued 370,000 options to management, key employees, and directors at a $2.30 exercise price and recorded $315,741 of related expense. It also issued shares for director and CEO services and recorded additional service-related expense.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expects existing cash and operating cash flow to provide liquidity for the next 12 months, but provides no quantitative revenue or earnings guidance. Management expects lower costs from the GNC centralized distribution transition to offset pricing discounts over subsequent periods and identifies additional GNC locations, new products, and international expansion as potential growth drivers.
Management states that the supply disruptions and order backlog are believed to be non-recurring. The filing also cautions that the transition-related pricing and distribution effects may continue to affect results. The company relies significantly on GNC and faces risks relating to customer concentration, competition, market demand, product performance, suppliers, personnel, and changes in accounting rules.
Pending matters include a potential California Proposition 65 labeling claim, for which the company cannot reasonably estimate potential exposure, and litigation concerning products containing Testofen. The company disputes the allegations and intends to defend the matters vigorously. No liability or loss range was recorded for these matters in the filing.
The company owns 100% of the Kaniwa protein extraction intellectual property. The USPTO did not allow its claims in December 2014, and the company filed a response on March 23, 2015. No impairment of long-lived assets was recorded. There were no reported defaults upon senior securities, related-party transactions, or material subsequent events.
Management concluded that disclosure controls and internal control over financial reporting were effective as of March 31, 2015. The filing does not include an independent auditor attestation of internal control effectiveness because the company qualifies for the applicable small-reporting-company exemption.
Important Facts for Investors to Verify
- Whether the $1.3 million order backlog and manufacturing disruptions were resolved and whether delayed orders converted into revenue after March 31, 2015.
- The sustainability of the improved gross margin after the GNC centralized distribution transition and the continuing impact of GNC pricing discounts and rebates.
- The May 15, 2015 maturity of the $437,089 revolving credit facility, including any renewal, repayment, or refinancing.
- Whether operating cash flow remains positive while revenue and profitability are under pressure.
- The magnitude and timing of any potential liabilities from the Proposition 65 notice and Testofen-related litigation.
- The effect of stock-based compensation, option issuances, and share repurchases on future earnings and dilution.
- The collectability of the increased accounts receivable balance and the company’s ability to realize its deferred tax assets and net operating loss carryforwards.